PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.64%
Negative EBIT growth while TRVN is at 10.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-22.65%
Negative operating income growth while TRVN is at 10.00%. Joel Greenblatt would press for urgent turnaround measures.
-23.20%
Negative net income growth while TRVN stands at 11.17%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-16.67%
Negative EPS growth while TRVN is at 14.37%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.50%
Negative diluted EPS growth while TRVN is at 10.78%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
5.52%
Share count expansion well above TRVN's 3.82%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.56%
Slight or no buyback while TRVN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-100.00%
Dividend reduction while TRVN stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-16.84%
Negative OCF growth while TRVN is at 8.63%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-16.73%
Negative FCF growth while TRVN is at 8.63%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6820.22%
Negative 10Y OCF/share CAGR while TRVN stands at 66.28%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
80.75%
5Y OCF/share CAGR 1.25-1.5x TRVN's 58.02%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
65.01%
3Y OCF/share CAGR at 50-75% of TRVN's 87.53%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-4282.29%
Negative 10Y net income/share CAGR while TRVN is at 71.64%. Joel Greenblatt sees a major red flag in long-term profit erosion.
64.75%
5Y net income/share CAGR at 75-90% of TRVN's 81.96%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
77.40%
3Y net income/share CAGR similar to TRVN's 83.68%. Walter Schloss would attribute it to shared growth factors or demand patterns.
285.15%
10Y equity/share CAGR 1.25-1.5x TRVN's 203.68%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
-96.49%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-92.46%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-49.30%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.76%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
23.04%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
21.61%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.